|
|
Volumn 4, Issue 11, 2007, Pages 626-627
|
|
Aromatase inhibitors and tamoxifen: Where do we go from here? Commentary
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
4 HYDROXYTAMOXIFEN;
ANTINEOPLASTIC AGENT;
AROMATASE INHIBITOR;
CYTOCHROME P450 2D6;
ENDOXIFEN;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ESTROGEN RECEPTOR;
LETROZOLE;
PROGESTERONE RECEPTOR;
TAMOXIFEN;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC ACTIVITY;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER HORMONE THERAPY;
CANCER RECURRENCE;
CANCER RESISTANCE;
CANCER SURVIVAL;
CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
DRUG ACTIVATION;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
DRUG FATALITY;
DRUG METABOLISM;
DRUG RESPONSE;
DRUG SAFETY;
DRUG WITHDRAWAL;
EARLY CANCER;
ENZYME ACTIVITY;
ENZYME INHIBITION;
GENE EXPRESSION PROFILING;
GENETIC POLYMORPHISM;
GENETIC VARIABILITY;
HAZARD RATIO;
HUMAN;
MONOTHERAPY;
PHARMACOGENETICS;
POSTMENOPAUSE;
PRIORITY JOURNAL;
RECURRENCE RISK;
RISK REDUCTION;
SECOND CANCER;
SHORT SURVEY;
STATISTICAL SIGNIFICANCE;
TREATMENT DURATION;
UNSPECIFIED SIDE EFFECT;
|
|
EID: 35649025764
PISSN: 17434254
EISSN: 17434262
Source Type: Journal
DOI: 10.1038/ncponc0955 Document Type: Short Survey |
|
Times cited : (2)
|
|
References (5)
|
